fda warning compounded tirzepatide warns compounding pharmacies on weight-loss drugs FDA warns Ozempic and Mounjaro

These compounded tirzepatide injections used the same subcutaneous delivery route as the FDA-approved products and theoretically offered similar bioavailability, since the route of administration was identical

Urticaria was not accompanied by respiratory, cardiovascular or gastrointestinal symptoms and disappeared spontaneously after the drug administration had stopped

Clinical data show that these symptoms are often temporary and tend to occur during dose escalation

Some patients experience the reappearance of issues they had before they started taking semaglutide, such as a more insatiable appetitethis can lead to subsequent weight gain